TDR and product/drug development
For the first 3 decades of TDR, much support went to product and drug development. Of the 18 new drugs or new drug combinations that have been registered internationally for TDR-targeted diseases since the 1970s, more than half resulted from TDR collaborations. TDR also helped to develop several of the public-private partnerships (PPPs) – Medicines for Malaria Initiative (MMV), the Foundation for Innovative New Diagnostics (FIND) and the Drugs for Neglected Diseases initiative (DNDi). We also established the African Network for Drugs and Diagnostics Initiative (ANDI) to help initiate both discovery and development. We have continued to support training and research fellowships to build national capacity to conduct clinical research, such as with the clinical research and development fellowships.
TDR is now focused on increasing access to new and improved products, rather than developing the products. We work closely with the product developers, national governments, research institutions and international organizations to identify barriers and expand access to these vital products to the most vulnerable groups.
WHO pre-qualifies the first artesunate suppositories for malaria
Pooling patient data could improve VL treatment options
Final workshop on conducting clinical research during disease outbreaks
TDR publications and articles
Celebrating 40 years of research
TDR: Health research that makes an impact
Using the TDR global competency framework for clinical research